文献速递妇科

BRCA突变卵巢癌患者接受奥拉帕利维持治疗中与延长缓解和生存相关的临床因素

Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
PubMed 文献 · Gynecol Oncol · 2019-10-08

这项欧洲8家医院的多中心回顾性研究纳入115例BRCA突变复发性上皮性卵巢癌患者,在铂类化疗后接受奥拉帕利维持治疗。中位随访21个月,中位无进展生存期(PFS)为12.7个月,中位总生存期(OS)为35.4个月。多因素分析显示,无铂间期≥12个月、完全缓解及CA-125正常化与延长的PFS和OS相关。

要点

  • 无铂间期≥12个月、完全缓解及CA-125正常化与延长的PFS和OS相关。
  • 中位随访21个月时,中位PFS为12.7个月,中位OS为35.4个月。
  • 研究为多中心回顾性设计,纳入115例BRCA突变复发性上皮性卵巢癌患者。

核心结论

  • 在复发性BRCA1/BRCA2突变卵巢癌患者中,末次铂类化疗后无铂间期≥12个月、完全缓解及CA-125正常化与接受奥拉帕利维持治疗时延长的PFS和OS相关。

研究设计与样本

  • 欧洲8家医院开展的多中心回顾性研究,纳入115例携带胚系或体细胞BRCA1/BRCA2突变、在铂类化疗后接受奥拉帕利维持治疗的复发性上皮性卵巢癌患者。

主要发现

  • 中位年龄54岁;90例为BRCA1携带者,24例为BRCA2携带者,1例同时携带BRCA1和BRCA2胚系突变。
  • 6例为体细胞突变(均为BRCA1),109例为胚系突变;90%为浆液性癌且为铂敏感。
  • 末次铂类化疗后,69%的患者CA-125水平正常化,87%达到RECIST客观缓解(部分缓解53%,完全缓解34%)。
  • 中位随访21个月,中位PFS为12.7个月,中位OS为35.4个月。
  • 多因素分析中,与奥拉帕利治疗下延长PFS相关的因素为:无铂间期≥12个月、RECIST完全缓解或部分缓解、末次铂类化疗后CA-125正常化;与延长OS相关的因素为无铂间期≥12个月、完全缓解及CA-125正常化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate clinical factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial ovarian cancer (EOC) patients with BRCA mutations and receiving olaparib as maintenance therapy in daily practice. METHODS: Multicenter (8 hospitals) European retrospective study of relapsing EOC patients having germline or somatic mutations of BRCA1/BRCA2 genes and treated with olaparib as maintenance therapy after platinum-based chemotherapy. RESULTS: One hundred and fifteen patients were included. Median age was 54 years. There were 90 BRCA1 carriers, 24 BRCA2 carriers and one patient had germline mutation of BRCA1 and BRCA2. Six patients had somatic mutations (all BRCA1) and 109 had germline mutations. Ninety percent had serous carcinomas and were platinum-sensitive. Following ultimate platinum-based chemotherapy, 69% of the patients had normalization of CA-125 levels and 87% had RECIST objective responses, either partial (53%) or complete (34%). After a median follow-up of 21 months, median PFS was 12.7 months and median OS was 35.4 months. In multivariate analysis, factors associated with prolonged PFS under olaparib were: platinum-free interval (PFI) ≥ 12 months, RECIST complete response (CR) or partial response (PR) and normalization of CA-125 upon ultimate platinum-based chemotherapy. Factors associated with prolonged OS were PFI ≥ 12 months, CR and normalization of CA-125. CONCLUSIONS: Platinum-free interval ≥ 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA1/BRCA2 mutated ovarian cancer patients who received olaparib as maintenance therapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Labidi-Galy SI, de La Motte Rouge T, Derbel O, et al. Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers. Gynecol Oncol. 2019. PMID: 31604666. doi:10.1016/j.ygyno.2019.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。